Akari Therapeutics (AKTX) Retained Earnings (2011 - 2026)
Akari Therapeutics (AKTX) reported Retained Earnings of -$279.0 million for Q1 2026, down 11.16% on a YoY basis from -$314.0 million in Q1 2025, and down 35578.39% sequentially from -$782000.0 in Q4 2025.
Akari Therapeutics (AKTX) Retained Earnings (2011 - 2026) Analysis & Trends
Akari Therapeutics (AKTX) has 16 years of Retained Earnings data on file, last reported at -$279.0 million in Q1 2026.
- For the quarter ending Q1 2026, Retained Earnings fell 11.16% year-over-year to -$279.0 million; the trailing twelve-month figure through Mar 2026 stood at -$279.0 million (down 11.16% YoY), and the FY2025 full-year result was -$782000.0, down 100.37% from the prior year.
- Retained Earnings slipped to -$279.0 million in Q1 2026, from -$782000.0 in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of $224.4 million in Q3 2025 to a low of -$279.0 million in Q1 2026.
- A 5-year average of -$51.4 million and a median of -$1.0 million in 2023 frame the typical range for Retained Earnings.
- Peak annual rise in Retained Earnings reached 24329.59% in 2025, while the deepest fall reached 100.37% in 2025.
- Tracing AKTX's Retained Earnings over 5 years: stood at -$217.5 million in 2022, then soared by 99.52% to -$1.0 million in 2023, then jumped by 20552.5% to $212.7 million in 2024, then slumped by 100.37% to -$782000.0 in 2025, then tumbled by 35578.39% to -$279.0 million in 2026.
- Business Quant data shows AKTX's Retained Earnings at -$279.0 million in Q1 2026, -$782000.0 in Q4 2025, and $224.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -527.87 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | -27.89 Mn |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -279.01 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 12.91 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 14.59 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 11.90 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -622,000.00 |
| 10 | Alnylam Pharmaceuticals | 36.08 Bn | 33.07 Bn | 959.66 Mn | -24.89 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -279.01 Mn |
| Dec 31, 2025 | -782,000.00 |
| Sep 30, 2025 | 224.37 Mn |
| Jun 30, 2025 | 220.85 Mn |
| Mar 31, 2025 | -251.00 Mn |
| Dec 31, 2024 | 212.71 Mn |
| Sep 30, 2024 | -926,000.00 |
| Jun 30, 2024 | -240.60 Mn |
| Mar 31, 2024 | -233.03 Mn |
| Dec 31, 2023 | -1.04 Mn |
| Dec 31, 2022 | -217.45 Mn |
| Dec 31, 2021 | -199.71 Mn |
| Dec 31, 2020 | -648,065.00 |
| Sep 30, 2020 | -175.47 Mn |
| Jun 30, 2020 | -617,622.00 |
| Mar 31, 2020 | -571,585.00 |
| Dec 31, 2019 | -348,860.00 |
| Sep 30, 2019 | -402,093.00 |
| Jun 30, 2019 | -154.49 Mn |
| Mar 31, 2019 | -245,258.00 |